uniQure (NASDAQ:QURE) Director Robert Gut Sells 2,726 Shares

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 2,726 shares of uniQure stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $73,765.56. Following the sale, the director owned 32,259 shares of the company’s stock, valued at approximately $872,928.54. This represents a 7.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Wednesday, June 10th, Robert Gut sold 7,552 shares of uniQure stock. The shares were sold at an average price of $26.05, for a total value of $196,729.60.

uniQure Stock Up 2.8%

Shares of uniQure stock opened at $27.57 on Friday. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The stock has a 50-day simple moving average of $22.52 and a 200-day simple moving average of $21.80.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, equities research analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Wall Street Analyst Weigh In

QURE has been the topic of a number of recent analyst reports. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Barclays cut their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. Cantor Fitzgerald reissued a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Finally, The Goldman Sachs Group raised their price objective on uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research note on Monday, April 20th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in QURE. Torren Management LLC bought a new position in uniQure in the 4th quarter worth approximately $28,000. Jones Financial Companies Lllp increased its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. IFP Advisors Inc bought a new position in uniQure in the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC bought a new position in uniQure in the 4th quarter worth approximately $48,000. Finally, CIBC Private Wealth Group LLC bought a new position in uniQure in the 3rd quarter worth approximately $50,000. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.